THE SPECTRUM OF BONE-DISEASE IN END-STAGE RENAL-FAILURE - AN EVOLVING DISORDER

被引:621
作者
SHERRARD, DJ
HERCZ, G
PEI, Y
MALONEY, NA
GREENWOOD, C
MANUEL, A
SAIPHOO, C
FENTON, SS
SEGRE, GV
机构
[1] UNIV WASHINGTON, SEATTLE, WA 98195 USA
[2] UNIV TORONTO, DEPT MED, TORONTO M5S 1A1, ONTARIO, CANADA
[3] MT SINAI HOSP, SAMUEL LUNENFELD RES INST, CLIN EPIDEMIOL UNIT, TORONTO M5G 1X5, ONTARIO, CANADA
[4] MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA
关键词
D O I
10.1038/ki.1993.64
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We have assessed the bone histology in 259 chronic dialysis patients, all of whom were in the same dialysis program. All patients had bone biopsies with quantitative histomorphometry, intact parathyroid hormone (PTH) measurements, basal and deferoxamine stimulated serum aluminum levels. Results demonstrate the increased incidence of the recently described aplastic bone lesion, particularly in patients treated with peritoneal dialysis (PD). Aluminum-related bone disease is much less common than previously described, perhaps in relation to the declining-use of aluminum as a phosphate binder. A different pattern of bone lesions is seen in PD as compared with hemodialysis (HD), with low turnover disorders comprising 66% of the lesions seen in PD and high turnover lesions accounting for 62% of the bone histologic findings in HD. The difference in these patterns may relate to alterations in PTH levels, as mean PTH levels in HD patients were 2-1/2 times the levels found in PD patients (P < 0.0005), while older age, higher prevalence of diabetes and a shorter duration of dialysis may also have contributed to the findings in the PD patients. We suggest that PD, perhaps by maintaining calcium at higher levels, may more effectively suppress the parathyroid gland.
引用
收藏
页码:436 / 442
页数:7
相关论文
共 36 条
  • [1] INTRAVENOUS CALCITRIOL IN THE TREATMENT OF REFRACTORY OSTEITIS FIBROSA OF CHRONIC RENAL-FAILURE
    ANDRESS, DL
    NORRIS, KC
    COBURN, JW
    SLATOPOLSKY, EA
    SHERRARD, DJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (05) : 274 - 279
  • [2] ANDRESS DL, 1986, J BONE MINER RES, V1, P391
  • [3] ANDRESS DL, 1987, J BONE MINER RES, V2, P525
  • [4] BONE HISTOLOGIC RESPONSE TO DEFEROXAMINE IN ALUMINUM-RELATED BONE-DISEASE
    ANDRESS, DL
    NEBEKER, HG
    OTT, SM
    ENDRES, DB
    ALFREY, AC
    SLATOPOLSKY, EA
    COBURN, JW
    SHERRARD, DJ
    [J]. KIDNEY INTERNATIONAL, 1987, 31 (06) : 1344 - 1350
  • [5] ANDRESS DL, 1985, VITAMIN D CHEM BIOCH, P926
  • [6] BERLAND Y, 1985, KIDNEY INT S17, V28, P183
  • [7] Brickman A S, 1980, Contrib Nephrol, V18, P29
  • [8] BRICKMAN AS, 1974, ARCH INTERN MED, V134, P883
  • [9] ALUMINUM LOCALIZATION IN BONE FROM HEMODIALYZED PATIENTS - RELATIONSHIP TO MATRIX MINERALIZATION
    COURNOTWITMER, G
    ZINGRAFF, J
    PLACHOT, JJ
    ESCAIG, F
    LEFEVRE, R
    BOUMATI, P
    BOURDEAU, A
    GARABEDIAN, M
    GALLE, P
    BOURDON, R
    DRUEKE, T
    BALSAN, S
    [J]. KIDNEY INTERNATIONAL, 1981, 20 (03) : 375 - 385
  • [10] HISTOPATHOLOGY OF RENAL OSTEODYSTROPHY WITH PARTICULAR REFERENCE TO EFFECTS OF 1 ALPHA-HYDROXYVITAMIN-D3 IN PATIENTS TREATED BY LONG-TERM HEMODIALYSIS
    ELLIS, HA
    PIERIDES, AM
    FEEST, TG
    WARD, MK
    KERR, DNS
    [J]. CLINICAL ENDOCRINOLOGY, 1977, 7 : S31 - S38